Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191801 · ClinicalTrials.gov registry record · Phase 3
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
A Phase 3 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 711
- Enrollment target
NCT01191801 is a Phase 3 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 711 participants.
The verdict
NCT01191801, a Phase 3 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 711 participants
- Enrollment target
Study Summary
This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
Interventions
- DRUG vosaroxin + cytarabine
- DRUG placebo + cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 711 participants |
| Start Date | 2010-12-17 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191801
The ClinicalTrials.gov registry entry for NCT01191801 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 711 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vosaroxin + cytarabine is the first listed.
NCT01191801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01191801 about?
NCT01191801 is a clinical study titled "Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML". This study compared treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.
What is the current status of trial NCT01191801?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 711 participants. The study started on 2010-12-17. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT01191801?
The interventions under investigation include: vosaroxin + cytarabine (DRUG), placebo + cytarabine (DRUG).
Who is sponsoring clinical trial NCT01191801?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.